At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Hepatoblastoma Treatment Study

Clinical Trial Title: 
Treatment of children with all stages of hepatoblastoma with temsirolimus (IND#122782, NSC#683864) added to high risk stratum treatment.
Clinical Trial Protocol ID: 
14111801-CAOI
Clinical Trial Investigator Name: 
Mary Lou Schmidt, MD
Clinical Trial Protocol Description: 

A risk-based treatment approach will maintain or improve event-free survival (EFS), decrease acute and long-term chemotherapy toxicity, and identify new agents in the treatment of children with hepatoblastoma.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are less than 21 years of age at the time of diagnosis.
  • Have been newly diagnosed with histologically-proven hepatoblastoma.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Pediatric Cancers and Blood Disorders
Contact Email: 
Contact Phone: 
(312) CANCER-1
Contact Name: 
Rush Cancer Center Clinical Trials Office